Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

ZIOPHARM Oncology logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Stock News Headlines

Best Global Universities for Oncology
Gold prediction: $5,000/oz. or higher is coming
The perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10
Alx Oncology Holdings (ALXO)
CG Oncology Inc
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
WBSPH 2024 - Oncology
See More Headlines

ZIOP Stock Analysis - Frequently Asked Questions

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD).

Company Calendar

Last Earnings
11/08/2021
Today
6/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
Employees
105
Year Founded
2005

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.98 million
Pretax Margin
-22,544.97%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:ZIOP) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners